Suzhou Kintor Pharmaceutical Inc,
18
1
2
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
11.1%
2 terminated/withdrawn out of 18 trials
85.7%
-0.8% vs industry average
22%
4 trials in Phase 3/4
17%
2 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males
Role: lead
To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects
Role: lead
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
Role: lead
Phase III Study of KX-826 With Adult Male Patients With AGA
Role: lead
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
Role: lead
The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC
Role: lead
Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)
Role: lead
A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors
Role: lead
Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness
Role: lead
To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia
Role: lead
A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients
Role: lead
A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects
Role: lead
Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029
Role: lead
Phase II Study Evaluating the Efficacy and Safety of KX-826
Role: lead
Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer
Role: lead
the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending
Role: lead
Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration
Role: lead
Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer
Role: lead
All 18 trials loaded